Adicet Bio (ACET) EBITDA (2017 - 2026)

Adicet Bio has reported EBITDA for 10 years, with the latest figure at -$22.3 million in Q2 2026.

• On a quarterly basis, EBITDA rose 31.15% year-over-year to -$22.3 million in Q2 2026; TTM through Jun 2026 was -$103.7 million, a 17.8% increase from a year earlier, with the FY2025 full-year figure at -$122.1 million, up 4.31% from the prior year.
• EBITDA was -$22.3 million for Q2 2026 at Adicet Bio, down from -$21.6 million in the prior quarter.
• The five-year high for EBITDA was $4.7 million in Q1 2022, with the low at -$52.3 million in Q3 2023.
• Average EBITDA over 5 years is -$28.8 million, with a median of -$31.2 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2023: EBITDA surged 122.04% in 2022, then sank 808.07% in 2023.
• Over 5 years, EBITDA stood at -$31.6 million in 2022, then declined by 0.0% to -$31.6 million in 2023, then climbed by 2.61% to -$30.7 million in 2024, then declined by 3.72% to -$31.9 million in 2025, then surged by 30.06% to -$22.3 million in 2026.
• The last three EBITDA figures came in at -$22.3 million (Q2 2026), -$21.6 million (Q1 2026), and -$31.9 million (Q4 2025), per Business Quant data.